DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Nucala" report has been added to ResearchAndMarkets.com's offering.
Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils. The drug inhibits the binding of IL-5 to the receptors on the surface of eosinophils, thereby reducing blood, tissue, and sputum eosinophil levels. Nucala gained US and EU approvals for use in asthma in November 2015 and December 2015, respectively. In Japan, the drug was approved in March 2016.
Key Topics Covered:
Product Profiles
Nucala: Asthma
Nucala: Chronic obstructive pulmonary disease (COPD)
List of Figures
Figure 45: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 46: Symbicort for asthma - SWOT analysis
Figure 3: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 46: Drug assessment summary of Symbicort in asthma
Figure 48: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Nucala drug profile
Table 2: Nucala pivotal trial data in asthma
Table 3: Nucala late-phase trial data in asthma
Table 4: Nucala Phase III trials in asthma
Table 5: Nucala drug profile
Table 6: Phase III clinical trials for Nucala in COPD
Table 49: Trelegy Ellipta Phase III trials in asthma
For more information about this report visit https://www.researchandmarkets.com/research/gfq3nt/nucala?w=4
